Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 8/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14470558 | 0.88 | CXCR3 (0.56) | CXCR3KMT2AATMRAB9AMAPT | |
| SCHEMBL5461816 | 0.87 | CXCR3 (0.73) | CXCR3KMT2AATMRAB9AMAPT | |
| SCHEMBL14373634 | 0.86 | CXCR3 (0.59) | CXCR3KMT2AATMBRSK1AURKB | |
| SCHEMBL14373603 | 0.86 | BRSK1 (0.74) | CXCR3KMT2AATMRAB9AMAPT | |
| SCHEMBL14373251 | 0.85 | CXCR3 (0.81) | CXCR3KMT2AATMRAB9AMAPT | |
| SCHEMBL5449881 | 0.84 | CXCR3 (0.77) | CXCR3KMT2AATMRAB9AMAPT | |
| SCHEMBL5461913 | 0.81 | CXCR3 (0.76) | CXCR3KMT2AATMRAB9AMAPT | |
| SCHEMBL14758273 | 0.81 | CXCR3 (1.00) | CXCR3KMT2AATMRAB9AMAPT | |
| SCHEMBL14373248 | 0.81 | CXCR3 (0.70) | CXCR3KMT2AATMRAB9AMAPT | |
| SCHEMBL14373259 | 0.81 | CXCR3 (0.70) | CXCR3KMT2AATMRAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | CXCR3 4743/4885KMT2A 1857/4885ATM 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.